Cybin Inc. Receives Schedule I Manufacturing License from DEA

Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM), has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“”). Granted for Cybin’s lab located in the Boston area, the license is required for investigators who plan to study, produce, analyze or otherwise work with Schedule I controlled substances. According to the announcement, the company is working to become a hub for innovation and drug discovery.

Cybin has relied on in-house capabilities as well as globally licensed research organizations in the United States, Canada, and the United Kingdom for most of its research and development (“R&D”).

With the license, the company anticipates expanding R&D efforts involving Schedule I compounds. The company also named Leah Gibson as its new vice president of investor relations. A life sciences investor relations leader, Gibson has more than 18 years of experience in corporate and shareholder communications as well as business strategy development. “We are pleased with the progression of our clinical and regulatory efforts since the company’s formation,” said Cybin’s CEO Doug Drysdale in the press release. “This new license further positions …

Full story available on Benzinga.com

More Cybin Inc. Receives Schedule I Manufacturing License from DEA